( t common psychiatric disorders in child...)12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system),Health

t common psychiatric disorders in children and adolescents. ADHD is a neurobiological psychiatric disorder that manifests as a persistent pattern of inattention and/or hyperactivity- impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

Shire ADHD Portfolio

Shire's portfolio of ADHD treatments includes VYVANSE(TM) (lisdexamfetamine dimesylate), the first prodrug stimulant, which is planned to launch June 2007, DAYTRANA(TM) (methylphenidate transdermal system), the first and only ADHD patch, and ADDERALL XR(R) (mixed salts of a single-entity amphetamine product), a long-acting formulated stimulant. Additional ADHD treatments under development by Shire include SPD465 (triple-bead mixed amphetamine salts) and SPD503 (guanfacine HCl extended release).

    For further information please contact:


    Porter Novelli for Shire


    Marion E. Glick

    212.601.8273

    917.301.4206 (on site at APA)

    


    Jennifer Anello

    212.601.8132

    203.470.0836 (on site at APA)

    


    APA# NR664

    May 23, 2007; 12:00 p.m. PDT (3:00 p.m. EDT)

    Sails Pavilion, Upper Level, San Diego Con
'"/>




Page: 1 2 3 4 5 6 7 8 9 
Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month
Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than
Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility